ApolloBio reports positive phase 3 results for INOVIO's VGX-3100

May 21, 2026 4:05 PM

ApolloBio announced positive topline results from its phase 3 trial of VGX-3100, a DNA immunotherapy developed by INOVIO Pharmaceuticals (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found